- Home
- XERS vs EOSE Comparison
XERS vs EOSE Comparison
Compare XERS & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- EOSE
- Stock Information
- Founded
- XERS 2005
- EOSE 2008
- Country
- XERS United States
- EOSE United States
- Employees
- XERS N/A
- EOSE N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- EOSE Industrial Machinery/Components
- Sector
- XERS Health Care
- EOSE Miscellaneous
- Exchange
- XERS Nasdaq
- EOSE Nasdaq
- Market Cap
- XERS 526.3M
- EOSE 542.2M
- IPO Year
- XERS 2018
- EOSE N/A
- Fundamental
- Price
- XERS $3.70
- EOSE $5.77
- Analyst Decision
- XERS Buy
- EOSE Strong Buy
- Analyst Count
- XERS 3
- EOSE 6
- Target Price
- XERS $4.87
- EOSE $5.42
- AVG Volume (30 Days)
- XERS 1.6M
- EOSE 8.4M
- Earning Date
- XERS 03-05-2025
- EOSE 03-03-2025
- Dividend Yield
- XERS N/A
- EOSE N/A
- EPS Growth
- XERS N/A
- EOSE N/A
- EPS
- XERS N/A
- EOSE N/A
- Revenue
- XERS $187,361,000.00
- EOSE $14,963,000.00
- Revenue This Year
- XERS $24.64
- EOSE N/A
- Revenue Next Year
- XERS $19.04
- EOSE $1,033.02
- P/E Ratio
- XERS N/A
- EOSE N/A
- Revenue Growth
- XERS 22.72
- EOSE 20.34
- 52 Week Low
- XERS $1.69
- EOSE $0.61
- 52 Week High
- XERS $3.87
- EOSE $6.64
- Technical
- Relative Strength Index (RSI)
- XERS 62.63
- EOSE 57.77
- Support Level
- XERS $3.47
- EOSE $5.29
- Resistance Level
- XERS $3.78
- EOSE $6.12
- Average True Range (ATR)
- XERS 0.16
- EOSE 0.63
- MACD
- XERS 0.03
- EOSE -0.07
- Stochastic Oscillator
- XERS 84.13
- EOSE 47.42
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.